Octagon Therapeutics
Octagon is focused on developing targeted medicines for autoimmunity. This new class of immunomodulators is activated by disease-related biology, ideal for episodic chronic disorders. A lead program inhibits autoreactive B-cells that drive pemphigus, RA, and other autoimmune diseases.
- Isaac Stoner COO
- Peter Yu CTO
- Fred Ausubel CSO
- Brent Cezairliyan VP Biology
- Nat Sherden VP Chemistry
- Luis Castillo-Menendez Principal Scientist
- Zhining Cao Senior Scientist